Protalix reports interim Phase II data for UC candidate

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) reported interim data from the first 14 patients with mild to moderate ulcerative colitis (UC) who completed

Read the full 231 word article

User Sign In